Renqi Pharmaceutical

Renqi Pharmaceutical is a China-based biotechnology company specializing in the development of innovative small molecule drugs, with a primary focus on Targeted Protein Degradation (TPD) technologies. The company leverages its proprietary platform to design Proteolysis-Targeting Chimeras (PROTACs) and molecular glues aimed at addressing previously undruggable targets in oncology and autoimmune diseases. Renqi's pipeline includes several early-stage programs targeting hormone receptors and transcription factors for the treatment of refractory cancers and chronic inflammatory conditions. Headquartered in Shanghai, the company is led by a team of industry veterans with extensive experience in medicinal chemistry and drug discovery from global pharmaceutical firms.